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Abstract 
The Effects of Cyclosporine on Bone Volume and Bone Formation Rate: 
A Dose Response Histomorphometric Analysis in the Rat Model 
Douglas M. Freedman and Gary E. Friedlaender 
Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New 
Haven, Connecticut 
Cyclosporine (CsA) is an immunosuppressive agent that has been associated with 
improved survival of vascularized solid organ and bone marrow transplantation, and 
recently has promise for the support of conventional or fresh, revascularized 
osteochondral allografts. The purpose of this study was to examine the effects of CsA on 
intact bone with the application of these findings to osteochondral allograft 
incorporation. Sprague-Dawley rats were randomly divided into six groups comprised 
of one control and five experimental groups. Each of the experimental groups received 
daily gavage administration of CsA dissolved in olive oil at one of the following dosages: 
2.5, 5.0, 7.5, 10.0, and 15.0 mg/kg/day. The control group received plain vehicle. 
Each group received four weeks of treatment, with gavage five times per week. Rats 
were sacrificed on day 28 and tail vertebrae were removed, fixed in ethanol 
undecalcified, sectioned, and coverslipped in preparation for light and fluorescent 
microscopic analysis. A histomorphometric analysis of trabecular bone volume and bone 
formation rate was performed on the slides using an Osteoplan computer software 
system. Blood was collected periodically during the study and serum osteocalcin levels 
were analyzed by radioimmunoassay. Results revealed a statistically significant dose- 
dependent increase in trabecular bone volume in all except the highest dose group. There 
were no significant changes in the bone formation rate, as well as no statistically 
significant changes in serum osteocalcin levels within or between groups over time. 
Similarly, there were no alterations in creatinine clearance rates of animals in the 
highest dose group. In summary, the effects of cyclosporine in this rat model appear to 
be manifested by an increase in trabecular bone volume, unchanged bone formation rate 
supported by unchanged osteocalcin levels, and a resultant proportionate decrease in 
bone resorption rate. These findings are consistent with a low state of bone turnover and 
thus a less than optimal environment for allograft incorporation. 

Table of Contents 
Introduction 1 
Cyclosporine. 1 
Structure/Background Information. 1 
Pharmacokinetics... 
Cyclosporine-Mediated Cellular Growth Regulation 
Immunosuppressive Actions. 
Therapeutic Effects. 
Therapeutic Monitoring and Dosage Regimens. 9 
Toxic Effects. 1 1 
The In Vitro Effects of Cyclosporine on Bone. 1 4 
The In Vivo Effects of Cyclosporine on Bone. 1 8 
Materials and Methods 2 2 
Results 2 5 
Light Microscopy. 25 
Fluorescent Microscopy. 2 5 
Osteocalcin (Bone Gla Protein, BGP) Radioimmunoassay. 2 6 
Discussion 4 0 
4 7 Bibliography 
-
£>
• 
GO
 
f\
3 

Table of Figures, Tables, and Photographs 
FIGURE 1: Atomic structure and alignment of amino acids of cyclosporine. 2 
FIGURE 2: Cellular site of T-lymphocyte inhibition by cyclosporine. 6 
TABLE 1: Recommended target ranges for cyclosporine concentrations (ng/ml) 
in whole bl d. 1 0 
TABLE 2: Relationship between dose of cyclosporine and serum concentration as 
measured by HPLC and RIA after renal transplantation. 1 0 
PHOTOGRAPH 1: Light microscope slide of trabecular bone. 2 3 
PHOTOGRAPH 2: Light microscope slide of growth plate. 2 3 
PHOTOGRAPH 3: Fluorescent microscope slide - double label. 2 4 
PHOTOGRAPH 4: Fluorescent microscope slide - single label. 2 4 
TABLE 3: Light Microscope Data. 2 7 
TABLE 4: Light Microscope Statistics. 2 8 
FIGURE 3: Bone Volume, Control and Experimental Groups. 2 9 
TABLE 5: Fluorescent Microscope D ta. 3 0 
TABLE 6: Fluorescent Microscope Statistics. 3 2 
FIGURE 4: Bone Formation Rate, tissue level - surface referent. 3 3 
FIGURE 5: Bone Formation Rate, tissue level - volume referent. 3 4 
FIGURE 6: Bone Formation Rate, cell level - surface referent. 3 5 
TABLE 7: Osteocalcin Data. 3 6 
FIGURE 7: Osteocalcin (OC) Levels, Days 0-24. 3 8 
TABLE 8: Creatinine Clearance - 15.0 mg/kg/day dose vs. control. 3 9 

Introduction 
Cyclosporin A (cyclosporine, CsA) is an immunosuppressive agent with selective 
T helper cell suppression. This drug has been associated with improved survival of 
vascularized solid organ (kidney, liver, pancreas, lung, heart) and bone marrow 
transplantation, and may also prove useful in support of conventional or fresh, 
revascularized osteochondral allografts. In addition, there are at least five autoimmune 
diseases in which cyclosporine has been consistently efficacious in experimental studies. 
In spite of its potentially serious primary side effect of nephrotoxicity, the use of CsA in 
conjunction with azathioprine and prednisone has been associated with a reduced 
incidence of allograft rejection, acute bacterial and fungal infections, as well as reduced 
morbidity 12,24,51,67,70,74,82,84,89 
If cyclosporine is to play an important role in musculoskeletal transplantation, 
its effects on intact bone, fracture healing, and osteochondral allograft incorporation 
must be understood. As well, the skeletal effects of CsA therapy may have important 
implications for its use in non-osseous transplants. The complex interactions now being 
clarified between the immune system and bone cell populations further underscore the 
importance of defining cyclosporine's effects on bone. 
The purpose of this study was to evaluate the dose dependent effects of 
cyclosporine at various dosages on the volume of trabecular bone, bone formation and 
bone resorption rates, and serum osteocalcin levels in a rat model. 
Cyclosporine 
Structure/Backqround Information 
Cyclosporine is a neutral, lipophilic, cyclic endecapeptide with a molecular 
weight of 1203. All eleven amino acids have the L-configuration of natural amino acids 
except D-alanine in postion 8 and N-methylglycine in position 3, and the amino acids in 
positions 11, 1, 2, and 3 form a hydrophilic active immunosuppressive site (Figure 1) 
2,5°. All natural and synthetic structural congeners with substitutions or deletions on 
the ring structure have less immunosuppressive activity than does CsA 97. CsA is 
produced as a secondary metabolite from a fungal strain, Tolypocladium inflatum Gams, 
originally retrieved from soil specimens in the high plains area of southern Norway, 
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FIGURE 1: Atomic structure and alignment of amino acids of cyclosporine 
[from Kahan 50] 
Hardangervidda, by Sandoz scientists 81. The number of solid organ transplant 
procedures performed annually has doubled since the introduction of CsA into clinical 
practice in December, 1983, 81 reflecting the enormous immunosuppressive 
effectiveness of this drug. 
Pharmacokinetics 
Cyclosporine is supplied as oral and intravenous preparations, stabilized with 
olive oil or castor oil vehicles, respectively. The relative bioequivalence of oral to 
intravenous doses is 1:3 50. There are threefold differences between individual patients 
in the average bioavailability of CsA (mean, 30 percent) and time to peak drug level 
(mean, 3.5-3.8 hours) as a result of slow, incomplete and variable gastrointestinal 
absorption Absorption is bile-dependent and adversely affected by biliary 
diversion, cholestyramine therapy, cholestasis, and slow gastric emptying; increased 
gastrointestinal mobility; steatorrhea; and reduced pancreatic exocrine secretion. The 
majority of CsA in the circulation is bound to lipoproteins of high, low, or very low 
density (34, 34, and 10 percent, respectively) and with chylomicrons 78. Some drug 
circulates unbound but this "free" fraction does not correlate with the total blood level 
or with toxic side effects. Distribution is 33 to 47 percent in plasma, 4 to 9 percent in 
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lymphocytes, 5 to 12 percent in granulocytes, and 41 percent in erythrocytes 25. The 
volume of distribution ranges from 4 to 8 liters per kilogram of body weight; the lack of 
correlation between volume of distribution and the presence of obesity suggests that 
factors other than the hydrophobicity of CsA are involved. 
Elimination is primarily by metabolism, with a median half-life of 6.4 to 8.7 
hours CsA is metabolized by the cytochrome P-450 hepatic enzyme system into 24 
metabolites, 90 percent of which are excreted in bile, with about 6 percent excreted in 
urine 25,5°. Coadministration of drugs that interact with the cytochrome P-450 
system may affect CsA metabolism. Cytochrome P-450 inhibitors known to increase 
CsA levels include ketoconazole, erythromycin, oral contraceptives, androgens, 
methylprednisolone, and calcium-channel antagonists; whether cimetidine and 
ranitidine inhibit CsA metabolism is controversial. Drugs known to induce the enzyme 
system and decrease cyclosporine levels include rifampin, phenobarbital, phenytoin, 
carbamazepine, valproate, and isoniazid. Children require more frequent and larger 
doses, as their clearance rate is 40 percent higher than that of adults. Drug clearance 
rates are slower in elderly patients and in patients with decreased levels of serum low- 
density lipoprotein triglyceride and cholesterol, and those with hepatic impairment. In 
the presence of elevated serum levels of bilirubin or alanine aminotransferase (ALT, 
SGPT), longer dosing intervals are necessary. In contrast, this change in administration 
pattern is not required with elevations of aspartate aminotransferase (AST.SGOT), 
lactate dehydrogenase, or alkaline phosphatase 10°. Because of the low level of urinary 
excretion, renal failure does not alter cyclosporine elimination. 
Cvclosporine-Mediated Cellular Growth Regulation 
Cyclosporine exerts varying effects on the growth of several cell types, and is 
currently known to inhibit helper and cytotoxic T cell activation and proliferation, 
possess antiparasitic and fungicidal activity, enhance IgE production and T-helper cell 
priming in antibody and in delayed hypersensitivity responses, reverse multidrug 
resistance to chemotherapeutic agents, and reduce or eliminate psoriatic skin lesions 
O -| 
. It is not currently known whether there exists a common molecular event that is 
controlled by CsA and responsible for these multiple actions. The most widely 
appreciated action of CsA has been its immunosuppressive action, and instead of 
suppressing the growth of all rapidly dividing lymphoid and myeloid cells as do cytotoxic 
drugs such as cyclophosphamide and azathioprine„ cyclosporine exerts its primary effect 
in a more selective manner. 
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Immunosuppressive Actions 
The most widely studied action of CsA is its ability to modulate the function of 
selective lymphocytic cell populations. The rejection of transplanted tissue are complex 
immune processes that involve the interaction and communication of several 
lymphocytic cell populations which, in turn, cause specific immunologic rejection 
patterns. The mixed lymphocyte reaction, in which cytotoxic T lymphocytes (CTLs) are 
generated and lymphokines are produced, is a widely used in vitro model of this process 
and is thus an informative system in which to study the cellular effects of CsA 81. In 
particular, this model requires appropriate cell-cell collaboration resulting in the 
generation of cytotoxic T lymphocytes capable of recognizing and killing the specific 
target antigen, and it is thought that the CTL together with helper T cells and lymphokine 
release play a major role in graft rejection. The induction of CTLs requires several 
steps in addition to antigen recognition, including presentation of antigen by 
macrophages with subsequent production and release of interleukin-1 (IL-1), 
activation of precursor CTLs with acquisition of receptor for interleukin-2 (IL-2), 
activation of T helper lymphocytes with production and release of IL-2 (production of 
IL-2 is accentuated by IL-1), clonal amplification of activated CTLs by IL-2 which in 
turn directly attack donor tissue causing cellular rejection, and activation of suppressor 
T lymphocytes that modulate these responses 2,81. The sites at which CsA exerts its 
inhibitory effect are thought to include the synthesis of IL-2 by T helper cells and to a 
lesser extent, the synthesis of IL-1 by macrophages/monocytes. CsA inhibition of IL-2 
production suppresses the activation and subsequent proliferation of CTLs and T helper 
cell subsets of the T lymphocyte population, effects which are concentration-dependent 
81. In contradistinction, proliferation, in the presence of IL-2, of T cells that already 
express the IL-2 receptor on their plasma membrane, is resistant to CsA even at high 
concentrations. In addition, another population of T cells that is resistant to CsA 
inhibition is suppressor T cells. The inhibition of T helper cell and CTL activation and 
proliferation by CsA, while sparing inhibition of suppressor T cell growth, is thought to 
be the key cellular event by which CsA prevents rejection and graft-vs-host disease and 
suppresses autoimmune diseases 88. 
An interesting and important observation is the Cd28 pathway of T cell activation 
and its CsA-resistant expression of the IL-2 gene 49. This pathway is functional in 
helper T cells, but is not utilized by suppressor T cells which are resistant to CsA. That 
these in vitro studies were demonstrated in lymphocytes obtained from healthy young 
adults raises the question of whether such a pathway is operational in transplant 
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patients experiencing acute rejection episodes despite adequate blood concentrations of 
CsA. 
The precise molecular mechanism of CsA's inhibition is not fully understood 
reflecting limited knowledge of the exact activation pathways in T lymphocytes. Evidence 
suggests that CsA is rapidly internalized through the plasma membrance by passive 
diffusion owing to its high hydrophobicity 2, and CsA-specific cell surface receptors 
have not been demonstrated. CsA does not affect the initial plasma membrane events, 
signal reception, transduction, and calcium influx (see Figure 2, Sites 1-4). 
Similarly, the alternate pathway which activates protein kinase C (Sites 5-6) is 
resistant to the drug. One theory of CsA's action implicates calcium-related cytoplasmic 
processes. Although CsA has only modest effects on calcium-channel permeability (Site 
2) or intracellular calcium mobilization (Site 8), amino acids 2 and 3 of cyclosporine 
display the characteristic Type 1-3 turn, which allows CsA to bind to calmodulin (Site 
9) 50. However, multiple inconsistencies limit the credibility of this theory that a 
receptor as ubiquitous as calmodulin can explain the T cell selectivity of CsA, including 
the fact that intracellular concentrations of CsA do not correlate with calmodulin content. 
A second theory proposes that CsA inhibits the enzymatic generation of activation 
protein (or proteins) that mediates signal transduction from the cytoplasm to the 
nucleus (Site 10). The generation of the cytoplasmic activation signal that triggers DNA 
synthesis by resting lymphocyte nuclei is reduced by cyclosporine 50 Cyclophilin, a 
cytoplasmic cyclosporine-binding protein, is one possible target of the cytoplasmic 
effect. This protein, a low molecular weight (17,737) basic protein binds CsA and its 
analogues in proportion to their immunosuppressive potency 35,50_ Cyclophilin has 
been shown to exhibit protein kinase activity and it has been proposed that this catalytic 
function may be involved in gene activation in T cells 85. In addition, pig-kidney 
cyclophilin has sequence homology with peptidyl-prolyl-cis-trans isomerase 28. This 
CsA-sensitive enzyme catalyzes cis-trans isomerization of proline imido peptide bonds, 
which may initiate folding of cytoplasmic proteins, thereby exposing DNA-binding 
domains 50. Thus, CsA could block T cell activation at the level of protein kinase- 
mediated gene activation, as well as at the level of a proline isomerase-mediated 
inhibition of DNA binding. 
A third potential site of action of CsA is the nucleus, as CsA selectively inhibits 
the capacity of nuclei isolated from human or rat lymphocytes, but not from liver, 
kidney, or tumor cells, to incorporate 2H-labeled thymidine 50. As well, the degree of 
impairment in nuclei isolated from the lymphocytes of different CsA-treated renal- 
transplant patients is inversely proportional to the intranuclear, but not serum, drug 
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FIGURE 2: Cellular site of T-lymphocyte inhibition by cyclosporine 
[from Kahan 50] 
concentrations 21. Thus, CsA potentially possesses inhibitory effects on transcrip¬ 
tional regulators (translocated cytoplasmic activation signals or independent intranu¬ 
clear proteins), thus inhibiting the production of multiple lymphokines (Site 11), 
enzymes necessary for cytoaggression (Site 12), or both. At therapeutic concentra¬ 
tions, CsA disrupts lymphokine and proto-oncogene c-myc mRNA synthesis, but not that 
of interleukin-2 receptor mRNA (Site 14), and at high concentrations, CsA may have 
tissue-specific effects on mRNA transcription (Site 13). CsA has no effect on events 
that occur after gene activation; it does not inhibit constitutive production of 
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lymphokines by T cell clones, the stability or translation of lymphokine mRNA in the 
cytoplasm (Site 14), or the export of protein products (Site 15) ^0. 
Therapeutic Effects 
In spite of its known toxicities, cyclosporine has drastically improved the 
clinical results of organ transplantation. It has significantly improved the initial 
survival of renal allografts, and has probably lengthened their long-term survival. CsA 
has substantially abrogated the impact of immunologic risk factors such as HLA 
mismatching and the absence of pretransplantation blood transfusions 50. It has reduced 
morbidity, the incidence of allograft rejection, the period of initial hospitalization 
(from 6 to 3 weeks, or less), and the rate of readmission 67-82. in addition, the 
absence of any myelotoxic effects permits faster alloengraftment 
It has been thought by numerous investigators that cyclosporine may have even 
greater utility in the treatment of autoimmune diseases, given their greater incidence 
and apparent high level of response. There are at least five autoimmune diseases which 
have been consistently responsive to CsA, although treatment remains investigational 
owing to its toxicity and relatively immediate relapses following discontinuation of 
therapy. In the most severe cases of psoriasis (defined as plaque-like psoriasis that 
covers at least 75 percent of the body and is unresponsive to other medications), CsA 
often produces a satisfactory if not complete remission. CsA offers a new approach to the 
treatment of the most severe cases of rheumatoid arthritis and related connective tissue 
disease, with responses comparable to those observed with other immunosuppressive 
agents. Most forms of autoimmune uveitis improve within a few weeks of treatment with 
CsA. In one three-year follow-up study, CsA was shown to be more effective than 
steroids or cytotoxic drugs in decreasing the inflammatory response and controlling the 
degree of vision loss from uveitis in Behcet’s syndrome; however, it was less effective 
in improving systemic symptoms of Behcet's syndrome 2^. In Type I diabetes mellitus, 
remission from insulin dependence can be induced by treatment with CsA instituted 
within two months after the initiation of insulin therapy. In one study, insulin was not 
required for a full year in 50 percent of patients treated 2^. Minimal-change focal and 
segmental, membranous, and IgA nephropathies are all sensitive to CsA, although it is 
not clear whether the reduction in proteinuria reflects healing of the basement 
membrane or a decrease in the glomerular filtration rate ^0. There appears to be little 
efficacy of CsA in the treatment of myasthenia gravis, systemic lupus erythematosus, 
autoimmune thrombocytopenic purpura, and Crohn’s disease. 
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Cyclosporine has an intrinsic antiparasitic effect in the rodent models of 
malaria, leishmaniasis, schistosomiasis, filiariasis, strongyloidiasis, and trichinosis 9. 
There is some evidence suggesting an anti-toxoplasma activity of CsA, although no 
protective activity was observed in a rat model with Pneumocystis carinii infection. 
CsA’s antiparasitic effects often seem to be host-mediated rather than directed against 
the parasite itself. It is not understood how the antiparasitic effects of CsA are mediated, 
and the clinical efficacy of CsA in parasitic infections remains unclear. 
Recent work has revealed that CsA potentiates the effect of some cytostatic drugs 
in vitro and in vivo, in normal and tumor cells 2^. A clear potentiation of cytostatic 
drugs is seen in cells with acquired and pleiotropic drug resistance, or multi-drug 
resistance, compared with their sensitive counterparts. Thus, CsA may have a role as a 
resistance modifier in multi-drug resistant tumor. Unfortunately, the suggested 
explanations for this most attractive phenomenon are contradictory, and must await 
further investigations for a thorough evaluation of the therapeutic potential. 
Extensive pharmacological studies on structure-activity relationships of 
cyclosporines began in the Sandoz laboratories in the mid-1970s with the goals of 
discovering a CsA derivative with: 1. much higher biological activity than CsA, 2. more 
selective spectra of activity than CsA, and 3. nonnephrotoxic effects while being 
equipotent to CsA. After much study, derivatives more potent than CsA itself and with 
acceptable side effects have not been found. (However, FK506, a chemically unrelated 
macrolide isolated from Streptomyces tsukubaensis, has been shown to have potent 
immunosuppressive activity at concentrations several hundredfold lower than CsA 34 
Studies of its clinical utility and side effects are ongoing.) Success has been quite 
limited in the search for a derivative with a narrow range of activity, with the most 
interesting profile being that of Val2dihydro-CsA (DH-CsA-D). This derivative affects 
allograft rejection only weakly while suppressing a variety of cell-mediated responses 
similar to CsA. DH-CsA-D was selected for the treatment of autoimmune diseases 
because it proved remarkably active in an experimental autoimmune disease in the rat 
and Rhesus monkey 9. Similarly, treatment with this analogue for a related disease in 
Lewis rats was found to be effective in preventing relapses after discontinuation of 
therapy, whereas a marked exacerbation of symptoms was noted after cessation of CsA 
therapy. Clinical efficacy of this derivative in a limited number of rheumatoid arthritis 
patients could not be conclusively established. Interestingly, DH-CsA-D had no obvious 
nephrotoxic effect, however due to other side effects, mainly hepatotoxicity and 
hypertension, clinical testing was abandoned 9. Finally, the reduced nephrotoxicity of 
the best-known CsA derivative, Nva2-CsA (CsA-G) initially raised hopes for a 
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nonnephrotoxic successor to CsA. In multiple in vivo tests, this derivative was usually 
found to be equipotent to CsA. Unfortunately, studies on toxicity have been rather 
confusing, yielding conflicting results in in vivo animal studies, most likely owing to the 
lack of standardized methods, the use of differing procedures, and strain and species 
variation 9. The search for a less toxic alternative to CsA continues, including further 
evaluation of CsA-G in clinical pilot studies. 
Therapeutic Monitoring and Dosage Regimens 
The obvious goal in cyclosporine therapy is to achieve blood levels within a 
“therapeutic window" such that higher levels with resultant toxicity and lower levels 
with diminished graft rejection activity can be avoided. Because of the significant intra- 
and interpatient variability in the absorption and clearance of CsA, regular monitoring 
of blood (serum or plasma) levels is performed to guide dosage sufficient for the narrow 
therapeutic window. It is preferable to measure trough levels just prior to the next 
administration rather than peak concentrations, as the latter do not occur at uniform 
times after dosage and do not correlate with the occurrence of toxic complications 52. In 
recipients of kidneys and bone marrow, trough serum levels above or below the 
therapeutic window correlate with episodes of graft rejection, nephrotoxicity, 
hepatoxicity, infection, and seizures. It is thought by several investigators that regular 
adjustment of CsA dosage to achieve and maintain trough levels within the narrow 
therapeutic range, rather than maintaining a fixed dose, may contribute to a further 
improvement of clinical outcome 50,81. Assessment of pharmacologic variables prior 
to transplantation has also been used to predict the dosage of CsA likely to achieve post¬ 
transplantation target levels. CsA levels are measured either by high-performance 
liquid chromatography (HPLC) or radioimmunoassay (RIA). HPLC measures only CsA, 
whereas RIA measures the parent compound plus certain metabolites. RIA measurement 
is used in routine clinical monitoring, and HPLC is used for patients with abnormal liver 
function. 
However, there are several problems with the monitoring of trough levels. 
Almost half of all renal transplant recipients have drug levels that are inconsistent with 
their renal status. In addition, the contribution of toxicity from CsA’s metabolites 
remains an area of debate. As well, blood concentrations of CsA may prove to be a poor 
reflection of the true concentration at receptor sites, and thus may be relatively useless 
as a predictor of the adequacy of therapy. 

The relationship between CsA concentration and graft rejection is clearly time 
dependent ^4. Based on the results of several studies comparing the clinical outcomes of 
transplant patients and trough blood concentrations of CsA, guidelines of recommended 
target ranges for CsA have been established (Tables 1,2). 
TABLE 1: Recommended target ranges for cyclosporine concentrations (ng/ml) 
O 4 
in whole blood [from Shaw ] 
Transplant First 3 to 6 months After 3 to 6 months 
 post-transplant post transplant 
Kidney 
Living-related donor 
Cadaver donor 
Serum creat >30 
Serum creat <30 
Liver 
Absence of toxicity 
Presence of toxicity 
Heart 
150-250 
mg/L 80-120 
mg/L 1 50-250 
250-350 
80-120 
350-450( d ay 1 - 7) 
250-350(day8-90) 
150-250(day 91 -1 80) 
80-125 
80-125 
80-125 
100-150 
100-150 
100-150(>day1 80) 
TABLE 2: Relationship between dose of cyclosporine and serum concentration 
as measured by HPLC and RIA after renal transplantation 
[from Keown et al. ®4] 
Time after renal Cyclosporine dose, po HPLC RIA 
transplant(mg/kg/day)(ng/ml) (ng/ml) 
7 days 
14 days 
1 month 
2 months 
3 months 
8.6 ± 1.0 
14.6 ± 3.3 
8.1 ± 2.4 
7.6 ± 1.8 
7.7 ± 2.2 
63 ± 24 
165 ± 39 
67 ± 21 
62 ± 21 
40 ± 11 
136 t 30 
209 ± 23 
156 ± 20 
99 ± 28 
79 ± 17 
In the first few weeks after transplantation, when the risk is greatest, rejection 
generally occurs when trough values are 170 ng per ml or less. A trough level around 
200 ng per ml usually prevents rejection. With progressive host-graft adapta¬ 
tion, requirements gradually diminish such that by three months post-transplantion, 
trough levels of 50 to 125 ng per ml are usually sufficient to maintain quiescence. The 
initial intravenous doses of CsA in renal-transplant recipients, based on drug clearance 

rates, have been calculated to achieve a steady-state concentration of 200 ng per 
milliliter, a level associated with a favorable balance between rejection episodes and 
nephrotoxic effects 58. This correlates with a predicted intravenous dose of 3.8 mg per 
kilogram per day (mean), on the basis of the linear relationship between the intra¬ 
venous dose and the steady-state concentration. The initial oral dose given to renal- 
transplant patients, generally 48 to 72 hours post-transplant) has been based on the 
linear relationship between the dose and the area under the serum concentration cun/e, 
but not on the trough value 50. The oral dosage predicted to achieve an average serum 
concentration of 200 ng per ml displayed a bimodal pattern: in the majority of patients, 
the mean dose was 6.0 mg per kg per day (3.0 - 10.0), but nearly 30 percent of 
patients required 11 to 25 mg per kg per day. Another investigator suggests an initial 
intravenous dose of 4.0 mg per kg over 24 hours and an initial oral dose of 10.0 mg per 
kg in two divided doses, both of which most nearly approximate the 200 ng per ml target 
level in renal transplant patients. The persistent and significant variability in CsA 
levels despite pharmacokinetic studies and drug level monitoring highlights the 
challenge in achieving the “optimal" cyclosporine dosage. 
Toxic Effects 
Cyclosporine has multiple toxic effects, yet nephrotoxicity is generally 
considered to be the most important. Some degree of renal impairment occurs in 25 
percent of renal transplant recipients, 38 percent of cardiac transplant patients, and 37 
percent of liver transplant patients 25. CsA causes at least a 20 percent reduction in 
renal function in almost all patients. The clinical course of patients with CsA-induced 
renal impairment is generally benign 58. in rat models, dose-response studies have 
shown that CsA nephrotoxicity is expressed acutely as a dose-dependent increase in renal 
vascular resistance, a decrease in renal blood flow, and a decrease in glomerular 
filtration rate (GFR) 81. In humans, as in rats, vasoconstriction is the characteristic 
hemodynamic event manifested by increased renal vascular resistance, decreased renal 
blood flow, decreased GFR, decreased urine output, and increased BUN-creatinine ratio 
54,81. Patients receiving CsA for the treatment of autoimmune disease with presumed 
normal renal function have markedly reduced glomerular filtration and effective renal 
plasma flow rates during the first week of therapy. A characteristic syndrome of 
increased serum creatinine concentrations, body weight, and blood pressure appears 
within one month 71. The mechanism of vasoconstriction is not entirely clear. One 
hypothesis is that CsA potentiates vasoconstrictor hormone-induced, transmembrane 

calcium-ion influx, causing an exaggeration in the contractile responses in arteriolar 
smooth muscle and mesangial cells. An interesting pharmacologic-clinical assessment of 
this theory is reflected in the current therapeutic trials of calcium channel blockers as 
preventive therapy in CsA-induced renal damage. The most favored hypothesis suggests 
that CsA influences the balance of the vasodilator prostacyclin and its vasoconstrictor 
antagonist thromboxane A2 in renal cortical tissue ^0. CsA consistently augments 
thromboxane A2 synthesis, although its effects on prostacyclin are controversial. The 
augmented thromboxane A2 synthesis produces renal vasoconstriction as well as 
proliferation of vascular smooth muscle cells into the intima with accumulation of 
cholesteryl esters in macrophages, converting them into foam cells. A single theory to 
link renal vasoconstriction with immunosuppressive drug effects hypothesizes that CsA 
inhibits gene transcription of critical humoral regulators of endothelial-cell or 
mesangial-cell production of local vasodilator substances necessary for normal vascular 
and glomerular interactions 50. 
Clinically, nephrotoxicity can be divided into acute, subacute, and chronic 
courses. The acute form begins during the first 7 days of treatment, the subacute form 
most frequently between 7 and 60 days, and the chronic form as early as 30 days. 
Approximately 30 percent of transplant patients treated with CsA will become 
oligoanuric within the first week of initiation of therapy. When the baseline GFR 
declines by more than 25 percent, the resulting renal impairment is classified as drug- 
induced nephrotoxicity, since this degree of dysfunction may not be completely 
reversible after cessation of drug therapy. It is likely that certain factors predispose to 
CsA-induced renal damage, including coadministered nephrotoxic drugs such as 
catecholamines, nonsteroidal anti-inflammatory agents, radiocontrast agents, 
amphotericin B, aminoglycoside antiobiotics, and trimethoprim plus co-trimoxazole; 
endotoxin; renal ischemic injury; and pre-existing kidney damage in non-renal- 
transplant patients 50-81. Clinicians often attempt to mitigate the early renal toxicity 
of CsA by administering it by continuous intravenous infusion. Avoidance of early 
exposure to CsA can be achieved by prophylactically administering polyclonal 
antilymphocyte serum to all kidney transplant recipients or to those with oligoanuria. 
Alternatively, initial therapy with azathioprine and prednisone reduces the risk of viral 
infection associated with antilymphoctye serum but increases the risk of acute rejection. 
Another option is to administer diltiazem immediately after operation which exerts 
cytoprotective effects and reduces intrarenal vasoconstrictive sensitivity to humoral 
stimuli, particularly angiotensin. However, diltiazem inhibits CsA metabolism, and 

thus markedly reduced doses of CsA must be employed, which by itself may explain the 
diminished renal toxicity. 
Subacute nephrotoxicity, a reversible injury, improves relatively promptly 
when the dose of CsA is reduced. Its clinical significance in renal transplantation occurs 
when it causes confusion between CsA nephrotoxicity and allograft rejection. Diagnosis 
is guided by several algorithms, with the putative diagnosis usually established 
according to the response of rejection episodes to corticosteroids and of toxic events to 
reduction of the CsA dose 
The course of chronic nephrotoxicity is variable, occuring in approximately 
10-15 percent of patients treated with CsA 50,54_ |n one group of cardiac transplant 
recipients receiving long-term treatment with CsA in doses of 10 to 17.5 mg per kg per 
day, the nephrotoxicity was found to be progressive. In contrast, renal-transplant 
patients have relatively stable reductions in renai function. A change from CsA to 
azathioprine results in a high risk of graft loss, suggesting ongoing, subclinical 
rejection. The most common approach is to reduce the dose of CsA to 2.5 mg per kg and to 
add azathioprine, although controlled studies are necessary to document the actual 
benefit of azathioprine in this setting ^0. 
Hepatotoxicity occurs in 4 to 7 percent of transplant patients and is 
manifested by cholestasis with hyperbilirubinemia and elevation of serum levels of 
aminotransferases in renal-transplant patients, particulary alanine aminotransferase. 
Neurologic side effects occur in about 20 percent of recipients of kidney and liver 
transplants, resulting in symptoms of tremor, burning palmar and plantar 
paresthesias, headache, flushing, depression, confusion, and somnolence. Gingival 
hyperplasia is a relatively common side effect, as is hypertrichosis of the face, arms, 
shoulders, and back, developing in at least 50 percent of renal transplant patients 
treated with CsA. Frequent reports of anorexia, nausea, or vomiting have been associated 
with the type of oral preparation, and are now known to be corrected by an alternate 
method of administration. CsA has no direct toxic effects on the structure and function of 
gastrointestinal mucosa, and the frequency of the common complication of acute 
pancreatitis is unchanged in the presence of CsA. There is a reduced incidence of 
bacterial and fungal but not viral infections as compared to regimens lacking CsA and 
using steroids, and this has been ascribed to a reduced requirement for steroids. All 
immunosuppressive agents increase the risk of malignancy, and lymphoma and epithelial 
malignancies develop in 0.1-0.4 percent of patients treated with CsA. There is an 
increased incidence of thrombosis of the arterial and venous limbs of renal allografts as 
well as systemic veins, and this is likely due, in part, to CsA's effects on thromboxane 

A2 release. CsA occasionally produces hyperglycemia, thought not to reflect any change 
in insulin’s response to glucose administration. Serum prolactin is increased and 
testosterone is decreased by CsA, causing gynecomastia in men, and impairing 
cn 
spermatogenesis or sperm maturation in rats . 
The In Vitro Effects of Cyclosporine on Bone 
It has been determined that certain components of the immune system play an 
important role in the regulation of normal bone remodeling. This school of thought has 
as its foundation the development of two inter-related observations: one, the 
controversial hematopoietic origin of the osteoclast; and two, the close association 
between inflammation and bone resorption as noted in rheumatoid arthritis and 
periodontal disease, and the identification of cytokines of immunocompetent cell origin 
capable of activating osteoclastic activity in vitro. 
Ever since the discovery of the osteoclast in 1873 by Kolliker 57 and despite 
intensive investigation using light microscopy, tissue culture, electron microscopy, 
microcinematography, autoradiography, parabiosis, quail chick nuclear markers, giant 
lysosomal markers in beige mice, Y chromosomes, bone marrow cell culture, and 
monoclonal antibodies, the origin of the osteoclast remains controversial. It is now 
generally agreed that osteoclasts are derived from mononuclear cells that originate in 
the bone marrow or other hematopoietic tissues and migrate to bone via the circulation. 
However, the exact identity of the mononuclear progenitor cell is unclear. Experiments 
by Walker in 1975 92'98 seemed to confirm the hematopoietic origin of the osteoclast, 
in which he showed that parabiotic union (vascular connection via a flap of skin) 
between a normal mouse and an irradiated osteopetrotic mouse would restore normal 
bone resorption in the affected animal 92. (Osteopetrosis, also known as Albers- 
Schonberg disease, is a congenital skeletal disorder caused by a failure of normal 
resorptive mechanisms in bone tissue resulting from a decrease in osteoclast activity.) 
Furthermore, Walker showed that injection of normal spleen or bone marrow cell 
suspensions into irradiated osteopetrotic mutants cured the osteopetrosis 93, whereas 
injection of cell suspensions from osteopetrotic animals into irradiated normal mice 
induced the disease 95. Kahn and Simmons 53 and later Jotereau and Le Douarin 48 used 
the quail-chick chimera to establish evidence pointing to the conversion of hematopoietic 
cells into osteoclasts. This system is based on the morphologic differences between the 
nuclei of the Japanese quail and the chick, and a chimera between a quail limb and bone 

rudiments grown on the chorioallantoic membrance of the chick embryo produced a 
proportion of osteoclasts with nuclei of both species. Using fluoride-inhibitable 
nonspecific esterase (NSE) as a marker of the cells of the mononuclear phagocyte (MNP) 
system and tartrate-resistant acid phosphatase (TRAP) as a lysosomal marker for 
osteoclasts, Baron et al. 6 have shown that mature osteoclasts and their mononuclear 
precursors share the NSE as well as a number of morphologic features. They conclude 
that mononuclear precursors of the osteoclast are members of the MNP lineage and 
differentiate early to acquire the properties of the osteoclast. However, the hypothesis 
that osteoclasts originate from monocytes/macrophages has been weakened by several 
observations, including a lack of Fc and C3 receptors and other macrophage-specific 
antigens on osteoclasts 13,39,80^ ancj e|ectron microscope differences between these 
two differentiated cell populations 13-19,43,44 jhus, although the osteoclast’s origin 
remains contested, most concur that a mononuclear hematopoietic-derived precursor 
cell, possibly from the MNP lineage or from a separate stem cell lineage, migrate to 
bone via the blood where they fuse to form multinucleated mature osteoclasts with the 
capacity for bony resorption. 
It has been known for some time that one of the manisfestations of an 
inflammatory response is bony resorption. Through histological studies, there is a clear 
association between the inflammatory infiltrate, composed of all types of leukocytes, and 
osteoclast-mediated bone resorption resulting in localized bone loss. It was proposed 
initially by Horton et al. 40 that an elaborated factor is responsible for the activation of 
osteoclasts and he termed this substance osteoclast activating factor (OAF). A 
lymphocytic source for OAF was shown in studies which disclosed that a radio-sensitive 
cell (lymphocyte) and not a radio-resistant cell (macrophage) was producing OAF in 
peripheral blood leukocyte cultures 41. The requirement for both lymphocytes and 
macrophages to produce OAF has been clearly demonstrated in the mouse model studying 
spleen cell suspensions, in addition to the inability of B cells to be productive of OAF 
These studies confirm reports in humans of an interaction between lymphocytes and 
macrophages necessary for the production of this lymphokine with its target cell the 
osteoclast 20,41,101,102 Biochemical studies have revealed that OAF is a protein in 
the 9 to 18 kD range 22,42,59,66 
To better understand the interactions of the immune system and bone turnover, a 
review of the events in sequential bone remodelling is helpful. A concept of primary 
importance in this process is the three levels of interaction: bone, bone marrow, and 
systemic components, the latter which include endocrine organs, other organs of the 
body, and the blood compartment. It is crucial to understand that both local and systemic 

factors contribute to bone remodelling, although systemic factors affect all levels of bone 
remodeling The actions of systemic factors are exerted through the regulation of 
calcium concentrations and by way of other organs affecting remodelling (e.g., parathy¬ 
roid gland, kidney), and local factors, as a result of their effects on bone marrow and 
directly at the level of the bone compartment. 
It is generally agreed that the process of bone turnover comprises a balance 
between resorption and formation, and that resorption and formation are closely coupled 
in space and time. During bone remodelling, formation occurs only after resorption and 
at the same site 30. Baron et al. 5 describe the process of bone remodelling, involving a 
series of several interactive events. The site at which bone activation normally occurs 
is an endosteal resting surface. Resting surfaces are the most prevalent surfaces in 
bone, representing 70-80% of the endosteal surface in humans. At this site can be 
identified the possible local generators of the initial event: bone matrix, bone 
extracellular fluid, endosteal lining cells, and osteocytes. Some alteration, such as 
conformational changes in matrix proteins or changes in fixed surface charge, may 
modify local cell configuration to initiate the process. The second event involves the 
transduction of the initial message from the bone matrix, bone extracellular fluid, or 
local bone cells, via the bone marrow, into a cascade of events resulting in local 
amplification of the initial event and local differentiation of osteoclast precursors. 
Lymphocytes and mononuclear phagocytes (MNP's), being acutely responsive, are the 
best candidates for cellular transducers, thought to act in concert by local lymphocytic 
proliferation with elaboration of OAF and other lymphokines. Stromal cells also 
influence the cellular milieu by releasing factors grouped under the term CSF (colony- 
stimulating factors) which regulate the local proliferation and differentiation of the 
mononuclear phagocyte and granulocyte lineages, in addition to constituting the origin of 
other bone remodelling cells: osteoblasts, osteocytes, and lining cells. The additive 
effects of the first and second events brings about the local formation of committed 
osteoclast precursors (OCPs), arising either from already committed hematopoietic 
stem cells or from the proliferation and differentiation of uncommitted hematopoietic 
stem cells within the mononuclear phagocyte lineage. OCPs, once formed, migrate to the 
remodelling site and attach to the bone surface, and it only when they are attached to the 
bone surface and perhaps even after initiating bone resorption that the mononuclear 
OCPs begin to fuse into multinucleated mature osteoclasts 90. The resorption process is 
considered to be initiated once there is formation of the multinucleated osteoclast. 
During this process, fusion, recognition, and attachment are ongoing. Fusion is 
asynchronous until the number of osteoclast nuclei reaches a maximum, at which time 

nuclei progressively "disappear." It is thought that the loss of nuclei is explained by 
intracellular digestion of nuclei (although evidence is lacking) or a fission mechanism 
whereby mononuclear "post-osteoclasts," perhaps MNP's, are dissociated. Evidence for 
fission exists in vitro and in vivo, although the fate of the cells after fission is not clear. 
The period following active resorption has been termed the reversal phase and is 
the transition zone between resorption and subsequent formation. At the end of 
resorption, mononuclear phagocytic cells appear in apposition to the bone surface. 
These cells arise either from chemotaxis and migration or osteoclast fission to form 
"post-osteoclasts," and may be involved in post-resorption scavenging and synthesis of 
future cement line components. These cells as well may be involved in the coupling 
phenomenon, although osteoclasts cannot be excluded from this role even though a period 
of a few days separates the phase of active resorption from formation. It may be 
significant that the osteoclast synthesizes and deposits a glucosamine-containing 
substance (lysosomal enzyme) at the bone surface which may act as a chemotactic 
component attracting fibroblasts (possibly stromal cell components of the bone 
marrow) and macrophages. Thus, lysosomal enzymes and/or other components of the 
cement line may represent the local coupling factor responsible for recruiting 
osteoblasts. Once the surface of the previously resorbed bone is coated with cement line 
components, the post-osteoclastic MNP's are replaced by young osteoblasts, which form 
osteoid. After a delay of a few days, the osteoid undergoes mineralization. Osteocytes are 
formed when a proportion of osteoblasts are incorporated into the matrix, whereas other 
osteoblasts remain at the bone surface as flat lining cells characteristic of resting 
surfaces. The balance of activating and inhibiting local and systemic factors determines 
the length of the resting phase and thus the rate of bone turnover. 
Because it has been suggested that immune cell derived regulators such as IL-1, 
IL-2, and OAF are involved in bone remodeling through calcemic hormones, studies have 
been undertaken to examine whether the immunosuppressive actions of cyclosporine 
would have an effect on the inhibition of bone resorption induced by calcemic hormones. 
Stewart et al. responding to the knowledge that multiple factors stimulate bone 
resorption including parathyroid hormone (PTH), prostaglandin E2, 1,25-dihydroxy 
vitamin D3 (1,25(OH)2D3), and OAF, wondered if administration of CsA could suppress 
the resorption induced by these factors. Using the fetal rat limb bone culture system, 
and measuring the amount of 45 Ca released into the medium, they found that indeed CsA 
inhibited bone resorption in a dose-dependent fashion induced by each of the afore¬ 
mentioned substances, and found that the inhibition of resorption by CsA was in fact 
reversible upon removal of CsA. Interestingly, this inhibition of resorption was 

observed with concentrations of CsA within the therapeutic range for human transplant 
patients. A related experiment by Klaushofer et al. using the cultured neonatal 
mouse calvaria system, yielded similar results where CsA inhibited bone resorption 
induced by the same factors less OAF, as well as thrombin, IL-1, and bacterial 
lipopolysaccharide. A continuation of these studies by the same authors 87 examined the 
interaction between CsA's and calcitonin's inhibition of bone resorption, again in the 
neonatal mouse calvaria culture system. The results revealed that unlike CsA, 
calcitonin's inhibition of PTH stimulated bone resorption was not a lasting inhibition; 
rather, an "escape" from inhibition was observed after 24 hours of organ culture. Of 
note, pretreatment or coincubation with CsA allowed the "escape" phenomenon to be 
delayed to 48 hours. 
The In Vivo Effects of Cyclosporine on Bone 
Until recently, there have been few studies designed to examine the in vivo 
effects of CsA on bone homeostasis. The first documentation of osseous effects arose from 
incidental findings in CsA-treated renal transplant patients, where persistent elevations 
of alkaline phosphatase (aP) were observed 58. In the European Multicentre Trial of 
CsA in renal transplantation, elevations of aP were attributed to hepatotoxicity 8, 
whereas Loertscher et al. were confident that the aP elevations were of an osseous 
origin, with suggestions of alterations in parathyroid hormone (PTH) as a contributory 
etiology. 
The majority of in vivo studies of CsA's effects on bone have been conducted in the 
rat model by Epstein et al. 64-65,79 jhis gr0Up performed histomorphometric 
analysis of rat tibiae, and has consistently found significant decreases in trabecular bone 
volume, and increases in bone formation rate and bone Gla protein (BGP, osteocalcin). A 
study comparing low dose CsA (7.5 mg/kg/day) with high dose CsA (15.0 mg/kg/day) on 
a short term (14 day) and long term (28 day) basis revealed significant decreases in 
bone volume in the high dose group on day 14 and in both the high and low dose groups on 
day 28. Osteoclast numbers (and thus bone resorption) were significantly increased in 
both low and high dose groups in the short and long term. Parameters reflecting bone 
formation rate including tetracycline-labeled surface and mineral apposition rate were 
significantly increased in the high dose group on days 14 and 28. In the low dose group, 
significant increases in tetracycline-labeled surface were seen on day 14, and increases 
in both parameters were present on day 28 84. In another protocol examining the 

effects of withdrawal of CsA 79, animals were divided into three groups, the first group 
receiving vehicle (no CsA) until sacrifice of rats at day 14 or day 28, the second group 
receiving CsA (15.0 mg/kg/day) until sacrifice of rats at day 14 or day 28, and the 
third group receiving CsA (15.0 mg/kg/day) for 14 days followed by vehicle until 
sacrifice at day 28. In addition, some animals from each of the first two groups were 
studied until day 49. Results of this experiment were consistent with those of their 
previous studies in that there was a significant decrease in trabecular bone volume, even 
after 14 days of CsA administration (55% of control), and this diminished further after 
28 days of CsA treatment (21% of control). In the third (withdrawal) group, continued 
diminution in bone volume was not observed after day 49 and, in fact, there was a 
suggestion of limited restoration, whereas in the second (CsA) group receiving CsA 
continuously, there was further decline in bone volume at day 49. As well, there were 
significant increases in bone formation rate, serum BGP levels, and osteoclast-like 
cells. 
Another study by Epstein's group ^ examined the histomorphometry of rat 
tibiae in oophorectomized rats with and without the presence of CsA, recognizing that 
acute estrogen deficiency yields high turnover bone remodeling. Their results revealed 
that the group of animals receiving CsA had a significant decrease in trabecular bone 
volume and an increase in parameters of bone formation and bone resorption compared 
with control animals and oophorectomized animals without CsA. 
Another group of investigators, Orcel et al., have studied the in vivo effects of CsA 
on caudal vertebrae of rats using histomorphometry Their protocol consisted of a 
14 day course of CsA at an oral daily dose of 7 mg/kg, and they found a significant 
decrease in bone resorption as assessed by active resorption surface and number of 
tartrate-resistant acid phosphatase-labeled osteoclasts. In addition, bone formation 
evaluated by double-labeled surface and endosteal appositional rate was increased 
proportionately for the decrease in resorption, and thus the trabecular bone volume in 
treated animals was not significantly changed. Friedlaender et al. 29 using rats treated 
with a course of CsA at 7 mg/kg/day for 14 days with follow-up through 16 weeks, 
found that there was no significant change in trabecular bone volume. In addition, 
significant decreases in bone formation rate assessed by double-label were noted 
throughout the 16 week period of observation, whereas bone resorption parameters 
including the number of osteoclasts were reduced at 2 and 4 weeks but increased at 16 
weeks. In related studies of CsA’s effects on intact and fractured bone in the rat, 
Friedlaender’s group found that a 14 day course of CsA at 7 mg/kg/day did not 

significantly alter the biomechanical properties of fracture repair or intact bone 
turnover 3U. 
Changes in bone homeostasis in human patients treated with CsA have been studied 
by only a few investigators. This has been examined primarily in CsA-treated renal 
transplant patients. The potentially confounding factor in examining bone histomor- 
phometry in renal transplant patients receiving CsA is the metabolic bone disease caused 
by renal osteodystrophy. This disease in manifested by osteoporotic signs and defects in 
bone formation and mineralization, and although it is thought that successful renal 
transplantation can mitigate this pathology, this point is not entirely clear 32,46 
Results of one review found abnormal (increased) numbers of osteoclasts and osteoblasts 
consistent with the “increasing repair hypothesis” 8. In another study of nine patients 
98, trabecular bone volume was normal but indices of osteoblast activity were increased 
with implicit increases in osteoclast activity and bone resorption. 
With the introduction of cyclosporine into clinical practice, the prospect of using 
revascularized osteochondral allografts for segmental bone defects has been realistically 
entertained. Previous modalities of treatment in musculoskeletal reconstruction have 
included free vascularized bone autografts from donor sites of fibula, rib, and iliac 
crest. However, in instances of massive bone defects following tumor resection or 
trauma, autografts frequently are insufficient. Current treatment involves amputation, 
the use of synthetics, or reconstruction with large, preserved, non-vascularized 
allografts. It is known that fresh bone is strongly antigenic wheras cartilage is only 
weakly so and possibly immunopriveleged 27,31,38. Experimentally, the intensity of 
response in animals relates directly to the genetic disparity between graft and recipient 
". While hypothesized, this same circumstance has not yet been confirmed in humans, 
nor has a direct correlation between the presence of anti-HLA immune responses and 
bone allograft "success." Deep frozen osteochondral allografts have reduced antigenicity, 
and while associated with considerable clinical success, their use engenders a high 
incidence of serious complications 60,61,63,72,91 Vascularized autografts of joints 
have been successfully transferred in recent years; however, clinical use is limited to 
the transfer of toe joints to the hand and of joints taken from amputated portions of 
extremities 26 
Despite the use of several drugs to suppress the immune response, vascularized 
allografts in animals have almost always been rejected within a few days. Now, with the 
advent of CsA, there has been dramatic improvement in the survival of a number of solid 
organ grafts, and there is evidence of success with osteochondral allografts, with two 
groups claiming long term survival of limb transfers in rats 37,55_ several recent 

studies in a number of animal models have assessed the survival of osteochondral 
allografts. In a study of revascularized rat knee allografts, Paskert et al. 73 examined 
the effects of continuous versus short-term (14 days) CsA (daily subcutaneous 
injection of 10 mg/kg) across either a weak or strong histocompatibility barrier. With 
a strong barrier, continuous CsA supported a successful graft, whereas short-term 
treatment, although without signs of rejection when followed 4 weeks, resulted in 
moderate rejection by 6 weeks. In the case of a weak immunogenetic barrier, both 
continuous and short-term CsA proved efficacious, without stigmata of rejection. In 
another investigation 43, rat hindlimb allografts were assessed in a similar way, with 
minor and major histocompatibility mismatch, receiving 16 days of subcutaneous CsA at 
a dose of 25 mg/kg/day. No evidence of allograft rejection was seen throughout the 
observation period of 16 weeks in the minor-mismatch group, whereas the major- 
mismatch group had a mean allograft survival time of 46.1 +/- 9.6 days. 
Various immunosuppressive regimens, including cyclosporine, were compared 
by Rodrigo et al. 77 based upon their ability to inhibit the appearance of antibodies to 
donor strain lymphocytes in rat recipients of distal femoral devascularized osteo¬ 
chondral allografts using a lymphocytotoxicity assay. The protocol included varied doses 
and durations of CsA therapy: 25 mg/kg/day for 14 days, 25 mg/kg/day for 24 days, 
and 15 mg/kg/day for 28 days. A marked suppression of antibody response was 
observed (85, 100, and 85% reduction of antibody responses respectively after 6 
weeks). These findings were superior to those of total lymphoid irradiation (30% 
positive antibody response), and courses of azathioprine/steroids or cyclophosphamide 
( ^ 50%). Related experiments by the same authors consisted of 9 dogs divided into 3 
autografts, 3 allograft controls, and 3 allografts treated with 25 mg/kg/day of CsA for 
one month. Despite the statistically insignificant number of animals, the 3 
immunosuppressed allografts were significantly superior to the control allograft dogs in 
the measured (clinical, histologic, immunologic, biochemical, roentgenographic, and 
gross autopsy) rejection parameters. 
In a similar study examining vascularized and non-revascularized dog knee joint 
allografts 26, the actual assessment of CsA (20 mg/kg/day) on the success of the 
transplantation was confounded by the coadministration of azathioprine. However, 
immunosuppression in vascularized allografts was successful for three of five animals 
(complications of failed vascular anastomosis and inadequate serum CsA levels resulted 
in the death of 2 animals), whereas both animals immunosuppressed for non- 
vascularized allografts had rapid rejection episodes. 

Materials and Methods 
Sprague-Dawley female rats weighing 200 ± 10 grams were randomly divided 
into six groups of twelve rats each, creating one control and five experimental groups. 
The animals were housed in AALAC approved animal housing facilities under normal 
circumstances and fed a diet of manufactured rat feed and water ad libitum. Cyclosporine 
(generously provided by Sandoz) was dissolved in pure olive oil and administered by 
gavage in 2 mg/ml solution, with the control group receiving plain vehicle. The five 
experimental groups each received the following dosage schedule of CsA: 2.5, 5.0, 7.5, 
10.0, and 15.0 mg/kg/day. Each animal underwent four weeks of treatment, with daily 
gavage five times each week. Tail vein blood was collected under ether anesthesia on days 
0, 3, 10, 17, and 24, and stored at -40 0 C until tested. Using a metabolic cage, urine 
was collected on day 28 from animals in the 15.0 mg/kg/day dosage group and stored at 
-40 0 C. Animals were weighed on days 0, 7, 14, 21, and 28. Calcein (DCAF, Merck) 
was given intraperitoneally at a dose of 30 mg/kg on days 13 and 27. 
On day 28, animals were sacrificed and the third tail vertebral body was removed 
and fixed in 40% ethanol at 4 0 C, and approximately 5 cc of blood retained from each 
animal. The tail vertebrae were dehydrated in a series of ethanol baths (70, 95, 100, 
and 100%) at 4 0 C, cleared in xylene, and embedded in methylmethacrylate according to 
the technique by Baron et al. 4. Vertebrae were sectioned on a Reichert-Jung microtome 
using a tungsten-carbide tipped blade into 4 micron and 12 micron sections. The 4 \i 
sections were deplastified and stained with toluidine blue 0 (Fisher) pH 3.7, cover- 
slipped with Permount (Fisher), and used for light microscope analysis. The 12 p 
sections were left undeplastified and unstained, coverslipped with Uvinert, a UV inert 
glue, and analyzed with the fluorescent microscope. All slides were read on a Zeiss 
Osteoplan system using commercially available software (Osteoplan, program by H. 
Malluche) to quantitate trabecular bone volume and bone formation rate indices. Data 
were subjected to analysis of mean, standard deviation, and standard error, and t-test to 
determine significance. 
Once thawed, tail vein serum was analyzed by radioimmunoassay to quantitate 
serum osteocalcin (BGP) levels. These data were subjected to analysis of mean, standard 
deviation, and standard error, with t-test and analysis of variance to assess significance. 
Photographs 1-4 represent the microscope images of both light and fluorescent 

23 
slides, showing both trabecular bone (photos 1-2) and fluorescent single and double 
label (photos 3-4) 
PHOTOGRAPH 1: Light microscope slide of trabecular bone 
PHOTOGRAPH 2: Light microscope slide of growth plate 
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PHOTOGRAPH 3: Fluorescent microscope slide - double label 
PHOTOGRAPH 4: Fluorescent microscope slide - single label 
•• r. 
Results 
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The following represent data collected from light microscopy, fluorescent 
microscopy, and osteocalcin radioimmunoassay. 
Light Microscopy 
The light microscopic analysis consisted of assessing the following parameters 
from the sections of rat tail vertebrae: trabecular bone volume, surface volume, and the 
diameter of trabecular bone. Table 3 contains the values for these parameters for each 
of the animals in the control and five experimental groups. Table 4 compares the 
experimental values with control values, using a student's t-test for assessment of 
significance. Figure 3 represents a comparison of trabecular bone volume among the six 
groups. 
There is a dose-dependent increase in trabecular bone volume, with a maximum 
reached at the 7.5 mg/kg/day dose, and a decrease in this parameter toward control with 
higher doses. There is a similar increase in trabecular surface volume with a maximum 
value also at the 7.5 mg/kg/day dose, and analogous decrease toward control value. The 
diameter of trabecular bone, as with trabecular bone volume and surface volume, is 
greater than control value for each of the experimental values. However, the peak value 
occurred at the 5.0 mg/kg/day dose, with a similar diminution of magnitude toward 
control value as the highest dose of 15.0 mg/kg/day is approached. 
Fluorescent Microscopy 
The following parameters were measured by fluorescent microscopy: mean 
distance between double label (MD-d), fraction of trabecular surface exhibiting double 
label (LAB-TS-d), fraction of trabecular surface exhibiting single label (LAB-TS-s), 
appositional rate per day (AR/D), bone formation rate: tissue level-surface referent 
(BFR ts), bone formation rate: tissue level-volume referent (BFR tv), and bone 
formation rate: cell level-surface referent (BFR cs). Table 5 contains the values for 
each of these parameters with mean, standard deviation, and standard error for each 
group. It should be noted that there are fewer observations than in the light microscopy 
data, since several slides had insufficient fluorescent label for accurate interpretation. 

Table 6 is a comparison of experimental versus control values for each of the 
fluorescent microscopy parameters, including a t-test analysis for significance. 
There were no statistically significant differences between experimental groups and the 
control group for any of the values with the exception of increases in MD-d, AR/D, and 
BFR cs in the 10.0 mg/kg/day dose group. Figures 4-6 represent intragroup 
comparisons of the three measurements of bone formation rate. 
Osteocalcin (Bone Gla Protein, BGP) Radioimmunoassay 
Serum osteocalcin levels were assessed by radioimmunoassay (RIA) from tail 
vein blood. Table 7 lists the osteocalcin values averaged per group compared to that of 
control values, including mean, standard deviation, and standard error, with analysis of 
variance to assess significance. Figure 7 represents the osteocalcin levels over time for 
each group. 
Table 8 represents creatinine clearance rates as assessed for animals in the 15.0 
mg/kg/day dosage group compared to those values obtained from control animals. 
There are clearly no statistically significant intra- or intergroup differences 
over time in osteocalcin levels. In addition, creatinine clearance rates of those in the 
highest dose CsA group are not reduced as compared to those of control animals. 

TABLE 3: Light Microscope Data 
GROUP Animal Bone Volume Surface Volume Diam Trab Bone 
control 1 1 6 221 5372 210 
1 33 209 421 7 252 
145 158 4123 1 95 
207 1 77 5380 167 
21 6 134 4698 1 46 
222 21 2 5396 200 
238 239 6986 1 74 
307 21 9 5432 206 
31 6 221 61 31 1 83 
325 256 5200 251 
335 237 5864 206 
.5 mg/kg 404 244 6062 205 
41 7 256 6301 207 
435 265 5812 232 
448 285 5236 277 
504 263 6303 213 
516 21 3 4443 244 
525 248 5537 228 
535 246 5883 213 
604 281 6786 211 
61 6 265 5584 242 
6252 221 4981 226 
637 232 5854 201 
.0 mg/kg 705 24 1 4769 257 
71 4 252 4325 296 
727 228 61 39 1 89 
737 202 5446 1 89 
805 294 61 09 245 
81 7 282 6069 236 
838 21 9 4328 258 
907 286 7431 1 96 
91 2 31 7 8016 201 
928 261 6348 209 
935 260 6249 212 
.5 mg/kg 1005 259 6506 203 
1016 266 6571 206 
1025 274 5876 238 
1038 229 51 36 227 
1 107 289 6221 237 
1118 243 5653 219 
1 1 25 193 5882 1 67 
1 1 34 353 6992 257 
1 208 265 6161 219 
1217 229 5678 205 
1 222 325 8449 1 95 
1234 264 5271 255 
1.0 mg/kg 1307 1 73 4231 209 
1316 240 61 64 1 98 
1324 292 7235 205 
1335 21 0 5525 1 94 
1417 267 61 82 220 
1424 244 5265 236 
1433 220 4479 250 
1 504 269 6063 226 
1516 227 6507 1 77 
1525 255 6273 207 
1 533 263 7464 1 79 
i.O mg/kg 1608 221 6481 1 73 
1614 203 5023 206 
1625 1 89 4930 1 95 
1637 24 7 5650 222 
1 707 21 2 5684 1 89 
1716 1 86 4806 197 
1 723 314 5664 282 
1 734 243 6042 205 
1 807 225 6034 1 90 
1817 198 5740 1 76 
1828 272 5900 234 
1832 197 5492 1 83 

TABLE 4: Light Microscope Statistics 
28 
cont vs. 2.5 
cont vs. 5.0 
cont vs. 7.5 
cont vs. 10.0 
cont vs. 15.0 
Bone Volume Surface Volume Diam Trab Bone 
cont value, avg 207.5 5345.4 199.1 
expt value, avg 251.6 5731 .8 224.9 
t-value 3.52 1 .27 2.27 
D.F. 21 21 2 1 
p < 0.05 yes no yes 
% change 21.3 7.2 1 3 
cont value, avg 207.5 5345.4 199.1 
expt value, avg 258.4 5929.9 226.2 
t-value 3.33 1.35 1 .89 
D.F. 20 20 20 
p < 0.05 yes no yes 
% change 24.5 10.9 1 3.6 
cont value, avg 207.5 5345.4 199.1 
expt value, avg 265.8 6199.7 219 
t-value 3.48 2.38 1 .64 
D.F. 21 21 2 1 
p < 0.05 yes yes no 
% change 28.1 1 6 1 0 
cont value, avg 207.5 5345.4 199.1 
expt value, avg 241 .8 5944.4 209.2 
t-value 2.3 1 .52 0.85 
D.F. 20 20 20 
p < 0.05 yes no no 
% change 34.3 11.2 5.1 
cont value, avg 207.5 5345.4 199.1 
expt value, avg 225.6 5620.5 204.3 
t-value 1.15 0.98 0.4 
D.F. 21 21 21 
p < 0.05 no no no 
% change 8.7 5.2 2.6 

B
on
e 
V
ol
um
e,
 
pe
rc
en
t 
o
f 
tr
a
be
cu
la
r 
bo
ne
 
(m
ea
n 
+ 
S.
E
.) 
2 9 
FIGURE 3: Bone Volume, 
Control and Experimental Groups 
Control 2.5 5.0 7.5 1 0.0 1 5.0 
□ Bone Volume 
p < 0.05 
Cyclosporine Dose (mg/kg/day) 

TABLE 5: Fluorescent Microscope Data 30 
Group Number MD-d LAB-TS-d L AB-TS-S AR/D BFR ts BFR tv BFR CS 
Controls 1 1 6 4.99 0.047 0.049 0.26 0.004 0.108 0.095 
1 33 6.332 0.178 0.16 0.33 0.021 0.432 0.12 
1 45 5.606 0.045 0.055 0.292 0.005 0.124 0.107 
207 6.955 0.05 0.081 0.363 0.007 0.2 0.132 
216 6.334 0.139 0.115 0.33 0.017 0.583 0.121 
222 6.989 0.117 0.133 0.364 0.016 0.394 0.133 
238 7.066 0.1 09 0.127 0.368 0.015 0.426 0.134 
307 6.397 0.099 0.061 0.334 0.012 0.299 0.122 
316 7.647 0.06 0.102 0.399 0.009 0.244 0.146 
325 7.585 0.095 0.126 0.395 0.014 0.277 0.144 
mean 6.59 0.0939 0.101 0.344 0.012 0.309 0.125 
S.D. 0.838 0.0442 0.0377 0.0437 0.0056 0.15 0.0159 
S.E. 0.265 0.014 0.0119 0.0138 0.0018 0.0475 0.005 
2.5 mg/kg 404 8.731 0.104 0.072 0.455 0.017 0.428 0.1 66 
417 5.049 0.047 0.079 0.263 0.005 0.1 12 0.096 
448 7.221 0.052 0.042 0.377 0.007 0.13 0.137 
504 6.126 0.123 0.087 0.319 0.014 0.342 0.1 1 7 
516 7.603 0.126 0.111 0.396 0.018 0.378 0.145 
525 9.976 0.091 0.076 0.52 0.01 7 0.385 0.19 
616 8.304 0.1 11 0.091 0.433 0.01 7 0.367 0.158 
6252 8.052 0.196 0.088 0.42 0.03 0.676 0.153 
637 6.543 0.036 0.153 0.341 0.004 0.112 0.125 
mean 7.512 0.0984 0.0888 0.392 0.0143 0.326 0.143 
S.D. 1.479 0.0498 0.0303 0.0772 0.0081 0.184 0.0281 
S.E. 0.493 0.0166 0.0101 0.0257 0.0027 0.0614 0.0094 
5.0 mg/kg 727 6.268 0.071 0.068 0.327 0.009 0.229 0.119 
737 5.793 0.078 0.091 0.302 0.009 0.231 0.11 
838 6.112 0.13 0.1 35 0.319 0.015 0.298 0.116 
mean 6.058 0.093 0.098 0.316 0.011 0.253 0.115 
S.D. 0.242 0.0322 0.034 0.0128 0.0035 0.0393 0.0046 
S.E. 0.14 0.0186 0.0197 0.0074 0.002 0.0227 0.0027 
7.5 mg/kg 1 005 6.136 0.063 0.057 0.32 0.007 0.184 0.11 7 
1 025 6.257 0.13 0.124 0.326 0.015 0.33 0.119 
1 038 7.352 0.061 0.041 0.383 0.009 0.191 0.14 
1 1 07 7.709 0.053 0.041 0.402 0.008 0.167 0.147 
mean 6.864 0.0768 0.0658 0.358 0.0098 0.218 0.131 
S.D. 0.785 0.0358 0.0396 0.0409 0.0036 0.0753 0.015 
S.E. 0.393 0.0179 0.0198 0.0205 0.0018 0.0377 0.0075 

TABLE 5: Fluorescent Microscope Data 
Group Number MD-d LAB-TS-d LAB-TS-s AR/D BFR ts BFR tv BFR cs 
10.0 mg/kg 1 31 6 8.779 0.032 0.04 0.458 0.005 0.139 0.167 
1 324 6.703 0.083 0.034 0.35 0 01 1 0.263 0.128 
141 7 6.475 0.07 0.056 0.338 0.009 0.199 0.123 
1 504 7.543 0.129 0.103 0.393 0.018 0.416 0.144 
1516 6.396 0.037 0.103 0.334 0.004 0.128 0.122 
1 525 8.948 0.142 0.084 0.467 0.024 0.593 0.1 7 
1 533 8.8 0.133 0.083 0.459 0.022 0.632 0.167 
mean 7.663 0.0894 0.0719 0.4 0.0133 0.339 0.146 
S.D. 1.165 0.046 0.0268 0.0607 0.0081 0.211 0.022 
S.E. 0.44 0.0174 0.0108 0.0229 0.0031 0.0796 0.0083 
15.0 mg/kg 1614 6.298 0.09 0.063 0.328 0.01 1 0.266 0.12 
1 625 6.325 0.074 0.076 0.33 0.009 0.232 0.12 
1 637 8.095 0.099 0.064 0.422 0.015 0.35 0.154 
1 707 6.795 0.07 0.083 0.354 0.009 0.242 0.129 
1 723 6.954 0.076 0.068 0.363 0.01 0.181 0.132 
1 734 6.018 0.07 0.125 0.314 0.008 0.2 0.115 
1 807 8.153 0.105 0.067 0.425 0.016 0.437 0.155 
mean 6.948 0.0834 0.078 0.362 0.0111 0.273 0.132 
S.D. 0.863 0.0145 0.0219 0.0449 0.0031 0.0907 0.0163 
S.E. 0.326 0.00547 0.00828 0.017 0.0012 0.0343 0.0062 
Index: MD-d: Mean distance between double labels 
LAB-TS-d: Fraction of trabecular surface exhibiting double labels 
LAB-TS-s: Fraction of trabecular surface exhibiting single labels 
AR/D: Appositional rate per day 
BFR ts: Bone formation rate, tissue level - surface referent 
BFR tv: Bone formation rate, tissue level - volume referent 
BFR cs: Bone formation rate, cell level - surface referent 

TABLE 6: Fluorescent Microscope Statistics 
MD-d LAB-TS-d LAB-TS-s AR/D BFR ts BFR tv BFR cs 
cont vs. 2.5 cont value, avg 6.59 0.0939 0.101 0.344 0.012 0.309 0.125 
expt value, avg 7.512 0.0984 0.0888 0.392 0.0143 0.326 0.143 
t-va lue 1.69 0.21 0.77 1.69 0.74 0.22 1.71 
D.F. 1 7 1 7 1 7 1 7 1 7 1 7 1 7 
p < 0.05 no no no no no no no 
cont vs. 5.0 cont value, avg 6.59 0.0939 0.1 01 0.344 0.012 0.309 0.125 
expt value, avg 6.058 0.093 0.098 0.316 0.01 1 0.253 0.115 
t-value 1.06 0.032 0.12 1.05 0.29 0.62 1.09 
D.F. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
p < 0.05 no no no no no no no 
cont vs. 7.5 cont value, avg 6.59 0.0939 0.101 0.344 0.012 0.309 0.125 
expt value, avg 6.864 0.0768 0.0658 0.358 0.00975 0.21 8 0.131 
t-value 0.56 0.69 1.56 0.56 0.74 1.13 0.58 
D.F. 1 2 1 2 1 2 1 2 1 2 1 2 1 2 
p < 0.05 no no no no no no no 
cont vs. 10.0 cont value, avg 6.59 0.0939 0.101 0.344 0.012 0.309 0.125 
expt value, avg 7.663 0.0894 0.0719 0.4 0.0133 0.339 0.146 
t-value 2.22 0.2 1.71 2.23 0.39 0.34 2.23 
D.F. 1 5 1 5 1 5 1 5 1 5 1 5 1 5 
p < 0.05 yes no no yes no no yes 
cont vs. 15.0 cont value, avg 6.59 0.0939 0.101 0.344 0.012 0.309 0.125 
expt value, avg 6.948 0.0834 0.078 0.362 0.01 11 0.273 0.132 
t-value 0.86 0.6 1.44 0.86 0.36 0.57 0.85 
D.F. 1 5 1 5 1 5 1 5 1 5 1 5 1 5 
p < 0.05 no no no no no no no 
Index: MD-d: Mean distance between double labels 
LAB-TS-d: Fraction of trabecular surface exhibiting double labels 
LAB-TS-s: Fraction of trabecular surface exhibiting single labels 
AR/D: Appositional rate per day 
BFR ts: Bone formation rate, tissue level - surface referent 
BFR tv: Bone formation rate, tissue level - volume referent 
BFR cs: Bone formation rate, cell level - surface referent 
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FIGURE 4: Bone Formation Rate, 
tissue level - surface referent 
control 2.5 5.0 7.5 1 0.0 1 5.0 
3 3 
□ BFR ts 
Cyclosporine Dose (mg/kg/day) 
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FIGURE 5: Bone Formation Rate, 
tissue level - volume referent 
□ BFR tv 
Cyclosporine Dose (mg/kg/day) 
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FIGURE 6: Bone Formation Rate, 
cell level - surface referent 
3 5 
0.2 -| 
* 
□ BFR cs 
* p < 0.05 
control 2.5 5.0 7.5 1 0.0 1 5.0 
Cyclosporine Dose (mg/kg/day) 

TABLE 7: Osteocalcin Data 
Group Animal Osteocalcin level, Day 0 Day 3 Day 10 Day 17 Day 24 
ng/ml: 
Control 1-1 65.6 77.9 61.2 65.6 96.9 
1-3 69.7 61 .2 69.7 63.8 73.8 
1-4 73.8 65.6 65.6 63.6 77.9 
2-0 68.9 71 .4 68.9 135.3 81 .6 
2-1 67.7 61 .5 69.7 67.7 77.9 
2-2 69.7 63.6 63.6 77.9 56.1 
2-3 61.5 71 .4 73.8 63.6 51 
3-0 76.5 82 66.3 77.9 69.7 
3-1 82 82 68.9 63.8 68.9 
3-2 82 102.5 63.8 82 71 .4 
3-3 61.2 69.7 61 .2 73.8 61 .5 
Mean 70.78 73.53 66.61 75.91 71.52 
S.D. 7.17 12.18 3.97 20.85 12.66 
S.E. 2.16 3.67 1.2 6.29 3.82 
mg/kg/day 4-0 56.1 89.3 61 .2 61 .2 66.3 
4-1 34.7 56.1 40.8 1 1 7.3 63.8 
4-3 38.8 51 61.2 1 02 53.6 
4-4 29.6 40.8 68.9 71 .4 56.1 
5-0 76.5 53.6 61.2 1 02 68.9 
5-1 76.5 61.2 89.3 66.3 61.2 
5-2 76.5 81 .6 89.3 107.1 132.6 
5-3 71.4 50 76.5 61 .2 51 
6-0 68.9 56.1 66.3 - 68.9 
6-1 1 02 56.1 86.7 89.3 56.1 
6-2 86,7 71.4 96.9 76.5 81.6 
6-3 66.3 53.6 66.3 147.9 53.6 
Mean 65.33 60.07 72.05 91.11 67.81 
S.D. 21.81 13.93 16.1 27.23 22.18 
S.E. 6.29 4.02 4.65 8.21 6.4 
mg/kg/day 7-0 68.9 68.9 86.7 43.9 66.3 
7-1 71.4 66.3 76.5 66.3 68.7 
7-2 68.9 68.9 81.6 81 .6 66.3 
7-3 71.4 81.6 81 .6 68.9 76.5 
8-0 71.4 76.5 1 02 81.6 81 .6 
8-1 63.8 56.1 68.7 53.6 68.9 
8-3 68.9 107.1 1 02 1 02 127.5 
9-0 68.9 96.9 68.7 1 02 71 .4 
9-1 96.9 96.9 117.3 96.9 127.5 
9-2 71.4 86.7 1 02 96.9 127.5 
9-3 71.4 63.8 68.7 66.3 71 .4 
Mean 72.12 79.06 86.69 78.18 86.69 
S.D. 8.53 16.2 16.63 20.02 26.58 
S.E. 2.57 4.88 5.01 6.04 8.01 

TABLE 7: Osteocalcin Data 3 7 
Group Animal Osteocalcin level, Day 0 Day 3 Day 10 Day 17 Day 24 
ng/ml: 
7.5 mg/kg/day 10-0 61.2 61.2 61 .2 81.6 81 .6 
10-1 89.3 76.5 63.8 68.9 53.6 
10-2 71.4 96.9 107.1 81 .6 53.6 
10-3 81.6 76.5 1 02 68.9 51 
11-0 43.4 63.8 63.8 66.3 63.8 
11-1 63.8 76.5 76.5 56.1 47.9 
11-2 43.4 107.1 86.7 71 .4 47.9 
11-3 61.2 56.1 76.5 66.3 53.6 
12-0 86.7 86.7 68.9 53.6 47.9 
12-1 56.1 89.3 86.7 71 .4 53.6 
12-2 107.1 53.6 76.5 81 .6 45.9 
12-3 76.5 68.9 68.9 63.8 50 
Mean 70.14 76.09 78.22 69.29 54.2 
S.D. 19.09 16.55 14.87 9.2 9.82 
S.E. 5.51 4.78 4.29 2.66 2.83 
10.0 mg/kg/day 13-0 79.1 79.1 74 68.9 79.1 
13-1 71.4 76.5 79.1 89.3 66.3 
13-2 74 104.6 66.3 84.2 66.3 
13-3 76.5 84.2 68.9 74 - 
14-1 81.6 89.3 117.3 76.5 68.9 
14-2 84.2 76.5 68.9 1 02 84.2 
14-3 79.1 76.5 96.9 66.3 89.3 
15-0 84.2 76.5 89.3 66.3 61.2 
15-1 74 81.6 68.9 76.5 66.3 
15-2 1 02 81 .6 79.1 79.1 76.5 
15-3 66.3 84.2 61 .2 71 .4 1 02 
Mean 79.31 82.78 79.08 77.68 76.01 
S.D. 9.3 8.35 16.44 10.78 12.83 
S.E. 2.8 2.52 4.96 3.25 4.06 
15.0 mg/kg/day 16-0 68.9 66.3 79.1 74 66.3 
16-1 79.1 74 132.6 140.3 89.3 
16-2 71.4 76.5 79.1 81.6 68.9 
16-3 68.9 71.4 74 66.3 61.2 
17-0 68.9 104.6 81.6 66.3 63.8 
17-1 79.1 81 .6 1 12.2 74 74 
17-2 74 84.2 79.1 76 5 76.5 
17-3 84.2 74 79.1 63.8 66.3 
18-0 76.5 76.5 61.2 79.1 66.3 
18-1 68.9 76.5 71.4 76.5 79.1 
18-2 58.7 71.4 71.4 61.2 58.7 
18-3 74 68.9 81 .6 76.5 68.9 
Mean 72.72 77.16 83.53 78.01 69.94 
S.D. 6.66 9.98 19.54 20.65 8.53 
S.E. 1.92 2.88 5.64 5.96 2.46 
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FIGURE 7: Osteocalcin (OC) Levels, Days 0-24 
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control 2.5 5.0 7.5 10.0 1 5.0 
H OC Day 0 
23 OC Day 3 
M OC Day 10 
□ OC Day 1 7 
□ OC Day 24 
Cyclosporine Dose (mg/kg/day) 

Mean 
S.D. 
TABLE 8: Creatinine Clearance - 15.0 mg/kg/day dose vs. control 
3 9 
Creat clearance (15.0 mg/kg/day) 
38.4 
17.5 
49.5 
10.7 
22 
12.9 
18.4 
11.8 
18.8 
33 
31.7 
33.6 
24.86 
12.19 
Creat clearance (control) 
15.6 
12.8 
21 .3 
16.1 
15.2 
25 
27.9 
14.8 
13.9 
21.3 
12.3 
17.84 
5.22 

Discussion 
40 
The objective of this project was to evaluate the effects of cyclosporine on intact 
bone homeostasis, as reflected in the trabecular bone volume and bone formation rate of 
tail vertebrae in the rat model. Five doses of CsA, ranging from 2.5 mg/kg/day to 15.0 
mg/kg/day, were employed, reflecting the range of dosage used in a variety of clinical 
regimens for transplant rejection prophylaxis and the treatment of autoimmune disease. 
Because of similarities between the rat and human with respect to the physiology of bone 
turnover, this rodent system has frequently been used as a model for evaluation of 
skeletal effects of therapeutic agents. 
This project is of interest for two major reasons. First, it is important to 
understand the osseous effects of cyclosporine since solid organ transplant patients are 
committed to a life-long course of treatment with this medication. It is valuable to 
demonstrate any alterations in bone homeostasis caused by this immunosuppressive 
drug. Second, based upon the success of CsA in solid organ transplantation, there is 
optimism about the success of vascularized bone allografts and perhaps enhanced 
behavior of conventional non-revascularized osteochondral allografts currently used in 
multiple clinical settings. Consequently, it is crucial to examine the systemic effects of 
this immunosuppressive agent on intact bone as well as any deleterious effects CsA may 
have on osteochondral or composite tissue allografts. 
In review, the results of this study revealed a dose-dependent increase in 
trabecular bone volume peaking at the intermediate dose of 7.5 mg/kg/day with no 
significant changes in bone formation rate as measured by double fluorescent label and 
no significant changes over time or dose in serum osteocalcin levels as assessed by 
radioimmunoassay. The significance of these data centers on the three following 
interrelated and normally linked parameters: trabecular bone volume, bone formation 
rate, and bone resorption rate. The net result of rates of formation and resorption 
dictate the bone volume, with increased bone formation and decreased bone resorption 
producing increased bone volume, and vice versa. Likewise, the speed of bone turnover 
is dependent on the bone formation rate and bone resorption rate. In this study, the bone 
volume is statistically significantly increased over control value at all doses except for 
15 mg/kg/day, and bone formation rate is unchanged as compared to control values at all 
doses. Therefore, the bone resorption rate must be decreased in proportion to the 

increases observed in trabecular bone volume. Similarly, with decreases in bone 
resorption rate, and no change in bone formation rate, bone turnover is also reduced. 
The process of bone remodelling has been described as a system of multiple 
interactions between bone, bone marrow, and systemic components. It is well known 
that this process involves a close coupling between resorption and formation, and that it 
is possible that lymphocytes and mononuclear phagocytes represent the cellular 
transducer responsible for the amplification of bone resorption activity at the cellular 
level. The lymphokine osteoclast activating factor (OAF), elaborated by T helper 
lymphocytes, is thought to be intimately involved in the initiation and amplification of 
the bone resorption process. In addition, interleukin-2 (IL-2) elaboration by T helper 
cells and interleukin-1 (IL-1) production by mononuclear phagocytes likely play a 
routine role in bone remodelling mediated through the calcemic hormones The 
mechanisms by which the calcemic hormones (parathyroid hormone [PTH], 
prostaglandins, and 1,25 vitamin D3 metabolites) induce bone resorption are not 
entirely clear. It is possible that immune cell factors such as IL-1, IL-2, and OAF 
increase the sensitivity of target bone cells to the resorbing actions of PTH, 
1,25(OH)2D3, and prostaglandins 22. In addition, PTH affects the proliferation of bone 
marrow hematopoietic stem cells mononuclear leukocytes have high affinity PTH 
receptors lymphocytes have functional receptors for calcitonin 82, and interactions 
between lymphocytes-macrophages and 1,25(OH)2D3 have been reported 1>88. 
Cyclosporine is thought to exert its inhibitory effects on resorption by reducing 
synthesis of IL-2 by T helper cells and IL-1 by mononuclear phagocytes 81. The 
inhibition of IL-2 production in turn suppresses the activation and proliferation of 
cytotoxic T lymphocytes and the feedback enhancement of additional T helper cell 
populations. Thus, the elaboration of other lymphokines, including OAF, will be 
diminished by CsA in therapeutic concentrations. It is tempting to speculate that CsA- 
induced inhibition of OAF, IL-1, and IL-2 contributes to the inhibition of osteoclast and 
thus bone resorption activity. The observation that two non-immunosuppressive 
analogues of CsA, cyclosporine H and cyclosporine F, do not inhibit bone resorption in 
vitro lends support to the hypothesis of lymphocytic involvement in bone homeostasis 
88. However, the fact that CsA inhibits bone resorption induced by a broad range of 
stimuli lends support to a more nonspecific action of CsA. 
A brief review of calcium and bone metabolism is helpful. An important function 
of bone is its storage of calcium, magnesium, phosphorus, sodium, and other ions, and its 
contribution to calcium homeostasis. The hormonal and ionic interactions in calcium 
homeostasis involve a close interrelation between parathyroid hormone (PTH), 

calcitonin (CT), and vitamin D, and the transport of calcium and phosphate by renal, 
intestinal, and bone cells. PTH acts directly on bone and kidney and indirectly on 
intestine through its effect on the synthesis of 1,25-dihydroxyvitamin D to increase 
serum calcium, and in turn, the concentration of PTH is closely regulated by a feedback 
mechanism dependent on the concentration of ionized serum calcium. Calcitonin is a 
physiologic antagonist to PTH and is a potent hypocalcemic, hypophosphatemic hormone, 
which acts to reduce bone resorption and increase renal calcium clearance. With 
adequate exposure to sunlight, vitamin D is actually a hormone. When skin is exposed to 
sunlight, 7-dehydrocholesterol is transformed into vitamin D3. In the liver, vitamin 
D3 is metabolized to 25-hydroxyvitamin D [25(OH)D] by vitamin D-25-hydroxylase, 
and this is loosely regulated by product feedback mechanism. In the kidney, 25(OH)D is 
metabolized by a number of enzymes, with 25(OH)D-a-hydroxylase producing 
1,25-dihydroxyvitamin D [1,25(OH)2D], the only known important metabolite of 
vitamin D. Metabolic influences operate on this hydroxylase to closely regulate the 
circulating concentration of 1,25(OH)2D. Under physiologic conditions, 1,25(OH)2D 
is believed to be synergistic with PTH in bone resorption. When serum calcium falls 
below normal, secretion of PTH is enhanced, resulting in increased production of 
1,25(OH)2D. 
Thus, there is a complex interaction between ionic and hormonal factors which 
exists to regulate serum calcium concentration, and this regulatory mechanism is highly 
dependent on bone. In certain clinical settings, the assessment of mineral metabolism is 
often complicated. Disturbances in mineral metabolism caused by renal failure can 
produce secondary hyperparathyroidism, where excessive production of PTH occurs 
because of partial resistance to the metabolic actions of the hormone. In progressive 
kidney disease, retention of phosphate because of reduced renal capacity to excrete 
phosphate and reduced concentrations of 1,25(OH)2D lead to hypocalcemia which in turn 
leads to reduced skeletal responsiveness to PTH and the development of secondary hyper¬ 
parathyroidism. Since calcium deposition in bone is critically dependent on the 
availability of phosphate, the retention of phosphate in renal disease facilitates calcium 
entry into bone and thus contributes to the hypocalcemia and elevations of plasma PTH. 
The bone disease in patients with secondary hyperparathyroidism is termed renal 
osteodystrophy, and concomitant osteomalacia (vitamin D deficiency) and osteitis fibrosa 
cystica (excessive PTH action) may also be seen. The significance of bone disease, 
therefore, in patients treated with cyclosporine is clear: the osseous effects of CsA may 
be obfuscated by chronic renal failure which necessitated kidney tranplantation, or 
concurrent renal disease in patients receiving CsA for other reasons. For the purposes 

of this study, then, knowledge of the state of mineral metabolism is helpful in 
interpreting the histomorphometric analysis of bone. Calcium, phosphate, vitamin D 
and PTH levels are not reported in this study, but in animals with no preexisting renal 
disease and with no changes in serum creatinine or creatinine clearances, it is safe to 
assume that there were no renal-induced alterations in bone and mineral metabolism. It 
can also be assumed, then, that any alterations in bone turnover as evaluated in this 
study were effected by cyclosporine. 
A simple explanation of the in vitro findings would suggest that there was 
inhibition of osteoclastic activity with resultant increases in bone volume, and without 
compensatory increases in osteoblastic activity, perhaps mediated through alterations in 
humoral factors (cytokines). There are, however, no in vitro studies reflecting CsA's 
effects on bone formation rate. In applying these findings to the phenomenon of coupling 
between osteoclastic bone resorption and osteoblastic bone formation, it would follow 
that CsA would effect a decrease in the bone formation rate, yielding a state of low bone 
turnover. It is possible, however, that CsA interferes with this coupled mechanism 
which may explain the discrepancy in some of the in vivo results. It is not fully clear 
whether an assessment of bone remodelling in vivo is entirely valid since there may be 
disturbances in this coupled homeostatic mechanism. 
Another explanation of the in vitro data is a direct toxic effect of CsA on 
osteoclasts. Epstein et al. suggest that this is unlikely because if true, one would also 
expect evidence of nephrotoxicity, which was not observed in their study or the present 
study. However, it is possible that in the absence of nephrotoxicity, osteoclasts exhibit a 
lower tolerance to the toxic effects of CsA. Studies of this nature have not been found in 
the literature. 
It is interesting to note that hypomagnesemia and decreased bone magnesium 
levels have been observed during CsA therapy This is of importance because the bone 
histological changes described with Mg deficiency are reductions in both bone resorption 
and formation 48. Although the present findings reveal only a decrease in bone 
resorption, it is interesting to consider the potential contribution of hypomagnesemia to 
these results. However, presuming the hypomagnesemic effects of CsA are mediated 
through effects on the kidneys, and considering the absence of changes in renal function 
assessed at the highest dose of CsA, it is unlikely that this could contribute to the findings 
of this study. 
The results of this in vivo study differ from the few other similar studies 
reported to date. Epstein et al. 63,64,78 found decreased trabecular bone volume, 
increased bone formation rate, and increased serum osteocalcin levels. Orcel et al. 68 
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discovered no change in trabecular bone volume and synchronous increases in bone 
formation and resorption rates. Friedlaender et al. 29 found no change in trabecular 
bone volume, decreased bone formation rate, and reduced bone resorption rate. Thus it 
is clear that the current findings of increased trabecular bone volume, decreased bone 
resorption rate, and unchanged bone formation rate represent yet another finding in the 
reported effects of CsA on rat bone histomorphometry. 
The osteopenia and increased bone formation rate observed by Epstein et al., 
consistent with a high bone turnover state, is found in the absence of changes in ionized 
calcium, phosphate, or PTH levels. This, in combination with unchanged creatinine 
levels, suggests that the effects of CsA are mediated at a cellular level via cytokines. 
These observations contrast with those in vitro, and these authors suggest that this may 
be explained by the fact that the whole animal is more representative of the multiple 
interactions between CsA and the cytokine system. Furthermore, they contend, their 
findings compare favorably to the bone histology from human renal transplant patients 
receiving CsA 3, as well as with the evidence of increased alkaline phosphatase of osseous 
origin reflecting increased bone turnover 88. In addition, Wilmink et al. 98 provide 
evidence of increased bone turnover with no changes in trabecular bone volume in CsA- 
treated renal transplant patients. The issue of renal osteodystrophy must be discussed in 
conjunction with these findings. After successful renal transplantation, patients may 
recover from metabolic bone disease; however, defects in bone formation, mineraliza¬ 
tion, and signs of osteoporosis may persist and even get worse 32,48. Thus, in these 
clinical examples of increased bone alkaline phosphatase and parameters of bone 
turnover, it is difficult to interpret these findings as resulting from an effect of CsA, 
persistence of metabolic bone disease, or a physiologic response to recovering 
osteodystrophy. 
In contrast, Orcel et al. have shown decreases in bone resorption which are 
supported by the in vitro findings, yet they observed increases in bone formation rate 
yielding a net absence of change in trabecular bone volume, again suggesting the 
hypothesis of a disrupted coupling phenomenon. They further suggest that the inhibitory 
effects of IL-1 on osteocalcin production by osteoblasts shown in vitro to be antagonized 
by CsA 82 may explain their findings of increased bone formation. These investigators 
found no evidence of renal toxicity or any modification of vitamin D metabolites, and thus 
a toxic effect of CsA to explain decreased osteoclast activity is unlikely. 
The findings of Friedlaender et al. to date have shown no changes in trabecular 
bone volume, decreases in bone formation rate, and proportionate decreases in bone 
resorption rate. Thus, they observed a low bone turnover state which persisted 16 

weeks after the initiation of the two week course of CsA. However, coupling between 
resorption and formation appears to be preserved. Thus, it remains uncertain whether 
the inhibition of resorption by CsA observed in vitro by Stewart et al. and in vivo by 
Friedlaender et al. is explained by an effect of CsA or is complicated by a nonphysiologic 
uncoupling of bone resorption and formation. 
The current findings of decreased bone resorption and no change in bone 
formation are consistent with the in vitro findings. As well, they support a 
disorganization in this coupling phenomenon. It remains unclear why there is such 
variability between investigators in the determination of the histomorphometric effects 
of cyclosporine in the rat. The present findings are consistent with a low bone turnover 
state as are those of Friedlaender et al. In contrast, Orcel et al. found essentially control 
values of bone turnover, whereas the results of Epstein's group support a high bone 
turnover state. In an application of these findings to an experimental design of osteo¬ 
chondral allograft survival, it would seem that the latter results would be optimal. A 
state of high bone turnover would intuitively support a more vigorous phase of bone 
remodelling and likely improve the success of the allograft. In regards to technique, 
there are minor variations in the dose and duration of therapy with CsA, however in each 
protocol presented here, anywhere from 7.0 to 15.0 mg/kg/day of CsA for 14 to 28 days 
has been used. This is not drastically different from the range of CsA of 2.5 to 15.0 
mg/kg/day for 28 days used in this study. Epstein et al. have mentioned a difference in 
technique as perhaps contributing to the different results. Their group performed 
histomorphometry on rat tibiae and not on rat tail vertebrae as was done in this study. 
Thus the issue of CsA differentially affecting weight-bearing versus non-weight¬ 
bearing bone is to be considered. One would conjecture that the degree of bone 
remodelling would be higher in bone exposed to the stress of weight, although how CsA 
would enter into this equation and either support or interfere with the preexisting 
histomorphometry is unclear. The age of the animals used differs among these studies. 
Epstein's group employed 250 gram, 300 gram, and 340 gram rats. Orcel et al. used 
weaning rats, Friedlaender et al. used 200-250 gram animals, and the current study 
employed 200 gram rats. It is possible that the bone remodelling sequence differs at 
different stages in the maturing rat. Thus, the varied results could represent a 
reflection of a differential effect of CsA on the bone remodelling sequence dependent on 
the age of the animal. The results of this study and those of Friedlaender et al. and Orcel 
et al. are the most similar, and have been derived from younger animals. In contrast, 
Epstein's findings, while entirely consistent in several studies, were derived from 
older, more mature animals. 
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The major shortcomings of this experiment involve the inadequate numbers of 
fluorescent slides used to assess values for bone formation rate. Several of the slides had 
such poor fluorescent label that analysis of them for double label would yield erroneous 
and non-reproducible results. This investigator is satisfied that the reading of the few 
well-labeled fluorescent slides is representative of actual findings, yet it remains 
unknown whether more appropriate numbers of slides would alter the bone formation 
rate results. Despite the relative paucity of fluorescent slides for analysis, the 
consistent absence of changes in osteocalcin levels in all groups over time is supportive 
of these results. 
Future studies are necessary to confirm or challenge these results. They should 
involve different durations of therapy with CsA and a comparison of histomorphometry 
between weight-bearing and non-weight-bearing bones. Bone histomorphometric 
studies of cyclosporine therapy in a rat model of renal failure and in rats 
immunosuppressed after renal transplantation would be most informative. 
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